28Jul 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors

Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors

The study revealed that patients with metastatic hormone-sensitive prostate cancer who do not achieve an optimal prostate-specific antigen (PSA) response during intensified androgen deprivation therapy have worse survival outcomes. The study examined 205 patients, where 66.3% achieved a positive PSA response (PSA nadir ≤0.2 ng/ml), while 33.7% had a suboptimal PSA response (PSA nadir >0.2 ng/ml). Those with a positive PSA response showed significantly improved progression-free survival and overall survival compared to the suboptimal response group.

  • #urology

Like

Save

Share